1. Home
  2. FMS vs UTHR Comparison

FMS vs UTHR Comparison

Compare FMS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fresenius Medical Care AG

FMS

Fresenius Medical Care AG

HOLD

Current Price

$23.53

Market Cap

13.5B

Sector

Health Care

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$493.41

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMS
UTHR
Founded
1996
1996
Country
Germany
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5B
20.3B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
FMS
UTHR
Price
$23.53
$493.41
Analyst Decision
Sell
Buy
Analyst Count
2
12
Target Price
$30.00
$495.08
AVG Volume (30 Days)
415.8K
411.6K
Earning Date
11-04-2025
10-29-2025
Dividend Yield
2.42%
N/A
EPS Growth
8.62
16.08
EPS
2.86
26.38
Revenue
$23,046,819,198.00
$3,128,400,000.00
Revenue This Year
$2.12
$13.64
Revenue Next Year
$2.92
$5.78
P/E Ratio
$15.87
$18.73
Revenue Growth
2.10
13.50
52 Week Low
$22.05
$266.98
52 Week High
$30.46
$496.73

Technical Indicators

Market Signals
Indicator
FMS
UTHR
Relative Strength Index (RSI) 45.83 65.89
Support Level $22.63 $474.59
Resistance Level $24.20 $489.99
Average True Range (ATR) 0.27 10.16
MACD 0.10 -0.69
Stochastic Oscillator 59.23 91.64

Price Performance

Historical Comparison
FMS
UTHR

About FMS Fresenius Medical Care AG

Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: